SUBSCRIBE
SUBSCRIBE
News   Drug Development

European Commission Awards Orphan Designation to Knopp NeuroSciences’ KNS-760704 in ALS

March 10, 2009 | 
1 min read
PITTSBURGH--(BUSINESS WIRE)--Knopp Neurosciences Inc. (“Knopp”) today announced that the European Commission (“EC”) has designated KNS-760704 as an orphan medicinal product for the treatment of Amyotrophic Lateral Sclerosis.
Clinical research Phase II
MORE ON THIS TOPIC
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Yellow Forklift truck truckraises a box over a stack of boxes and red arrow down. Decrease in economic rates, low demand for goods, decrease in import or export. Reduced storage, logistics costs
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac